Diagnostics Device Identifies Cervical Cancer

The ZedScan I device uses electrical impedance spectroscopy (EIS) to provide accurate and real-time detection of neoplasias in cervical disease, aiding better targeting of a biopsy site by providing a more accurate assessment of the cervix, reducing the number of unnecessary diagnostic biopsies. The EIS measurement detects changes to cells as they progress from normal to precancerous and then to cancerous, helping colposcopists develop a future real-time model for cervical intraepithelial neoplasia (CIN)2/3 diagnosis and treatment.

The system consists of a cordless handheld device and a base unit, together with a single-use disposable sleeve. Among the features of the device are wipe-clean surfaces, an on-board user interface, built-in quality control tests, and real time results that can be transferred to a personal computer (PC) for data storage and report generation. The ZedScan I device is a product of Zilico (Sheffield, United Kingdom), and has received the European Community (CE) marking of approval.

“ZedScan has the potential to make a significant impact on how women are managed within the cervical cancer pathway by providing better information to the clinician in real-time, and its European approval is an important advancement for clinicians, healthcare systems, and patients,” said Sameer Kothari, CEO of Zilico. “We now look forward to being able to satisfy the growing demand as colposcopy clinics seek to implement this breakthrough system and exploit the clinical and health economic benefits it will bring through better patient management.”

Related Links:
Zilico